liu.seSök publikationer i DiVA
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
The effect of genetic variability on drug response in conventional breast cancer treatment
University of Aarhus, Denmark.
University of Aarhus, Denmark.
2009 (Engelska)Ingår i: European Journal of Pharmacology, ISSN 0014-2999, E-ISSN 1879-0712, Vol. 625, nr 1-3, s. 122-130Artikel, forskningsöversikt (Refereegranskat) Published
Abstract [en]

The conventional breastcancer diagnosis based mainly upon histopathology, hormone and HER-2 receptor status, will in the future be combined with information on genomic and epigenetic profiles of the individual patient. This will lead to an optimal personalized therapy, directed towards specific genomic aberrations, avoiding unnecessary toxicity, side effects and chemotherapeutic drugs for which the patient evolves resistance. Breastcancer is a very heterogeneous malignancy, expressing a considerable variation in genomic aberrations from deletions and amplifications comprising entire chromosomes to minor regions. A wide spectrum of differently expressed genes and mutations has been identified, adding information to the highly complex picture of the tumor genome. The vast majority of breastcancer incidents is of somatic origin and may be caused by a combination of the individual genetic profile and environmental exposure. A major contributor to the variation in genetic profile is the single nucleotide polymorphisms (SNPs), which are highly abundant throughout the genome, and both current and future methodologies have the potential to screen millions of SNP genotypes in one analysis. Identification of specific SNP genotypes affecting transcriptional activity and thereby the outcome for the patient, of genes involved in DNA repair, metabolizing of chemotherapeutic drugs and drug target genes will determine the outcome for the patient. This will be an essential part of the development of personalized treatment of cancer. In this review the focus is on clinically relevant SNPs in genes implicated in drug metabolism and disposition as well as their influence on breastcancer therapy toxicity and/or efficacy.

Ort, förlag, år, upplaga, sidor
Elsevier, 2009. Vol. 625, nr 1-3, s. 122-130
Nyckelord [en]
Personalized medicine; Breastcancer; Drugresponse; SNP; Chemotherapy
Nationell ämneskategori
Medicin och hälsovetenskap
Identifikatorer
URN: urn:nbn:se:liu:diva-85189DOI: 10.1016/j.ejphar.2009.08.045PubMedID: 19836373OAI: oai:DiVA.org:liu-85189DiVA, id: diva2:566575
Tillgänglig från: 2012-11-08 Skapad: 2012-11-08 Senast uppdaterad: 2017-12-07

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMed

Personposter BETA

Wiechec, Emilia

Sök vidare i DiVA

Av författaren/redaktören
Wiechec, Emilia
I samma tidskrift
European Journal of Pharmacology
Medicin och hälsovetenskap

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 71 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf